Krystal Biotech Beheer
Beheer criteriumcontroles 4/4
De CEO Krystal Biotech is Krish Krishnan, benoemd in Dec2015, heeft een ambtstermijn van 8.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.22M, bestaande uit 11.8% salaris en 88.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.43% van de aandelen van het bedrijf, ter waarde $ 297.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 6.4 jaar.
Belangrijke informatie
Krish Krishnan
Algemeen directeur
US$6.2m
Totale compensatie
| Percentage CEO-salaris | 11.8% |
| Dienstverband CEO | 8.9yrs |
| Eigendom CEO | 5.4% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 6.4yrs |
Recente managementupdates
Recent updates
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$52m |
| Jun 30 2024 | n/a | n/a | US$106m |
| Mar 31 2024 | n/a | n/a | US$57m |
| Dec 31 2023 | US$6m | US$733k | US$11m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$3m | US$645k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$130m |
| Jun 30 2022 | n/a | n/a | -US$115m |
| Mar 31 2022 | n/a | n/a | -US$104m |
| Dec 31 2021 | US$7m | US$581k | -US$70m |
| Sep 30 2021 | n/a | n/a | -US$58m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$764k | US$498k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$631k | US$366k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$13m |
| Dec 31 2018 | US$705k | US$200k | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$69k | US$69k | -US$8m |
Compensatie versus markt: De totale vergoeding ($USD 6.22M ) Krish } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.74M ).
Compensatie versus inkomsten: De vergoeding van Krish is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Krish Krishnan (59 yo)
8.9yrs
Tenure
US$6,223,894
Compensatie
Mr. Krish S. Krishnan, M.S., M.B.A., is Founder of Krystal Biotech, Inc. since December 2015. He has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since December 2015. Mr. K...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 8.9yrs | US$6.22m | 5.43% $ 297.5m | |
| Founder | 8.9yrs | US$3.84m | 5.53% $ 302.9m | |
| Executive VP & Chief Accounting Officer | 4.8yrs | US$2.57m | 0.045% $ 2.5m | |
| General Counsel & Corporate Secretary | no data | geen gegevens | geen gegevens | |
| Vice President of North American Sales & Marketing | no data | geen gegevens | geen gegevens | |
| Head of U.S. Sales & Marketing | less than a year | geen gegevens | geen gegevens | |
| Vice President of Corporate Development | no data | geen gegevens | geen gegevens | |
| Director of Human Resources & Operations | no data | geen gegevens | geen gegevens | |
| Senior VP & GM of Europe | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Development | 2.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Patient Access | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Global Value and Access | less than a year | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van KRYS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 8.9yrs | US$6.22m | 5.43% $ 297.5m | |
| Founder | 8.8yrs | US$3.84m | 5.53% $ 302.9m | |
| Lead Independent Director | 8yrs | US$610.32k | 0.37% $ 20.4m | |
| Independent Director | 7.4yrs | US$584.82k | 0.27% $ 15.0m | |
| Independent Director | 5.7yrs | US$585.07k | geen gegevens | |
| Independent Director | 2.8yrs | US$570.44k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$568.32k | 0% $ 0 | |
| Non-Employee Independent Director | 7.2yrs | geen gegevens | geen gegevens | |
| Independent Director | 1.7yrs | US$934.43k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 4.8yrs | geen gegevens | geen gegevens |
6.4yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van KRYS wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.4 jaar).